Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2013
Reporting Period: This filing is a current report dated October 30, 2013, and does not cover a specific financial reporting period (e.g., quarterly or annual). It serves to disclose a specific event occurring on or before this date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of an investor presentation rather than a financial statement.
Material Changes
Regulation FD Disclosure (Item 7.01): The company disclosed certain slides used in an investor presentation dated October 2013. These slides are attached as Exhibit 99.1 and are intended for use in subsequent presentations to analysts and stockholders.
Legal Status of Disclosure: The information is furnished pursuant to Item 7.01 and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934. It will not be incorporated by reference into registration statements unless specifically identified.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing references Exhibit 99.1, page 2, for a discussion of forward-looking statements and associated risks and uncertainties. The filing itself does not detail specific guidance numbers or risk factors but directs readers to the attached presentation for this information.
Unusual Items: None reported in the text of the 8-K itself, other than the standard disclosure of the investor presentation materials.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation dated October 2013) for specific financial projections, pipeline updates, and strategic outlook.
- Consult page 2 of Exhibit 99.1 for the detailed discussion of risks and uncertainties related to forward-looking statements.
- Verify that the information in the presentation has not been superseded by subsequent filings or announcements.
- Note that the content of this 8-K is not legally "filed" for liability purposes under Section 18 of the Exchange Act.